Search results | glaxosmithkline


Partnering Agreements with GlaxoSmithKline

This report provides all the information you require to better understand GlaxoSmithKline and its partnering interests and activities over the past seven years.


GlaxoSmithKline looks to sell it older drugs

GlaxoSmithKline  has invited private equity firms to consider making offers for a range of its older drugs sold in Western markets, according to three people with direct knowledge of the matter.


GlaxoSmithKline (GSK) is a top pharmaceutical company based in London, United Kingdom and Philadelphia, USA

Pharma rumor mill: GlaxoSmithKline forges ahead with hunt for Chinese vaccine partners

In the pharma rumor mill: GlaxoSmithKline may be suffering through a corruption scandal in China, but that hasn’t interfered with its plans to team up with a Chinese company on vaccines.

Pharma rumor mill: Sanofi, Novartis & GlaxoSmithKline all in race to buy Elder Pharma

Elder Pharmaceuticals shares rose after reports in the pharma rumor mill that Sanofi, Novartis & GlaxoSmithKline are all in race for their acquisition.

Aspen proposed big pharma deals with GlaxoSmithKline for Arixtra and Fraxiparine asset purchase

GlaxoSmithKline, a big pharma company, is discussing pharma deals for the sale of its thrombosis drug brands Arixtra and Fraxiparine, along with a related French factory, to Aspen Pharmacare in a deal that could be worth some $1 billion.

GlaxoSmithKline (GSK): Company profile

GlaxoSmithKline, a top pharmaceutical company, is reviewed in terms of partnering, licensing and M&A interests and activity over recent years

GlaxoSmithKline: M&A activity 2005-2013

GlaxoSmithKline has also announced 16 M&A deals since 2005, with the lead deals being the acquisition of Human Genome Sciences and Stiefel

GlaxoSmithKline: Partnering activity 2005-2013

GSK announced over 380 partnering / licensing deals since 2005, with 50 deals in 2012 alone. Analysis of the partnering deals shows a strong emphasis on partnerships in oncology, infectives, central nervous system and gastrointestinal diseases

Partnering with GlaxoSmithKline: Partners for innovation and success

GlaxoSmithKline is a top pharma company active in partnering, licensing and M&A in pharmaceuticals and consumer healthcare

Is GlaxoSmithKline readying to spin off older products?

The announcement that GSK intends to create a separate division around its mature brands sparks spin off speculation


Sorry, your search returned no results.


GlaxoSmithKline sells Aspen Pharmacare $853 million equity stake

GSK has agreed to the sale of 28.2 million ordinary shares in Aspen Pharmacare Holdings

GE and GlaxoSmithKline form biotech partnering for tumour genetic disorder

GE Healthcare announced an biotech partnering agreement between its affiliate, Clarient Diagnostic Services and GlaxoSmithKline.

GlaxoSmithKline signs pharma alliances with Gates Foundation

GlaxoSmithKline and Sanofi have both signed for a pharma alliances to work with the Bill & Melinda Gates Foundation.

GlaxoSmithKline big pharma partners Immunocore for oncology and viral disease treatment

Immunocore Limited has entered into a partnership with pharma partners GlaxoSmithKline for multiple novel targets not addressable using antibody-based technologies.

GlaxoSmithKline gives $23.5 million seed funding for start-up companies

GlaxoSmithKline is investing $23.5 million in seed funding for a new venture fund to invest in drugs for rare diseases, underscoring the growing role of big drugmakers in backing start-up companies.

Johnson & Johnson, and GlaxoSmithKline big pharma deals Index Ventures for $11 million in grants

Johnson & Johnson, and GlaxoSmithKline have entered pharma deals for early grants for a new kind of anticoagulant drug they believe may prevent dangerous blood clots without causing bleeding – a previously unachievable goal.

M&A news: GlaxoSmithKline acquires Okairos in $324 million deal

M&A news: GlaxoSmithKline has acquired Okairos, a specialist developer of vaccine platform technologies for €250 million (approximately £215 million/$325 million) in cash.

GlaxoSmithKline big pharma deals with DKSH for antibiotics

Big pharma company, GlaxoSmithKline, has signed a pharma deals agreement with DKSH for them to provide contract sales services in both private clinics and trade channel for the big pharma company’s antibiotic product line.

Is GlaxoSmithKline readying to spin off older products?

The announcement that GSK intends to create a separate division around its mature brands sparks spin off speculation

GlaxoSmithKline big pharma partners Avalon for $495 million life sciences start-ups

Big pharma company, GlaxoSmithKline, pharma partners Avalon Ventures in order to bankroll a crop of drug-hunting life sciences start-ups in a $495 million joint venture.